LGALS3 and congestive heart failure: In patients undergoing primary percutaneous coronary intervention for ST elevation MI, circulating galectin-3 levels were significantly higher than in healthy subjects, and elevated circulating level of galectin-3 was the strongest independent predictor of the combined 30-day major adverse clinical outcome (defined as advanced congestive heart failure or 30-day mortality) [114].